Cardiotoxicity of Immune Checkpoint Inhibitors with Anthracycline Chemotherapy in Triple-Negative Breast Cancer
Background/Aim: The addition of an immune-checkpoint inhibitor (ICI) to chemotherapy improves outcomes in both early-stage and metastatic triple-negative breast cancer (TNBC). However, ICIs are associated with immune-related adverse events (irAEs), such as cardiotoxicity, raising concerns for patients receiving both an...